Sangamo Therapeutics thinks it's found a faster, earlier pathway to approval for its Fabry disease gene therapy. The biotech ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may ...

Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the ...

A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as ...

Samsung Biologics has so far secured at least five major contracts this year, and its latest with an unnamed Asia-based ...

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...

APRIL antibody has passed a registrational test in a rare kidney disease, marking a significant win from its 2018 buyout of ...

Plus, news about Annexon, Passkey Therapeutics, XOMA Royalty and Twist Bioscience: MacroGenics sells breast cancer drug rights for up to $75 million: The company is ...